This document discusses oral contraceptive pills, specifically those containing progestogens like desogestrel. It provides information on the history and development of oral contraceptives, including how progestogen formulations have evolved to reduce androgenic side effects. Clinical trial results are presented showing that contraceptives containing desogestrel have good cycle control and low rates of side effects. Desogestrel is highlighted as having favorable characteristics like high selectivity and specificity for progesterone receptors over other steroid receptors.
1. The document discusses new concepts in infertility including updated WHO reference values for semen analysis, the use of ICSI for male factor infertility, and success rates varying based on the cause of infertility.
2. ICSI, where surgically retrieved sperm are injected into eggs, has become an established procedure for couples with male subfertility to have a biological child, with reassuring post-natal outcomes reported so far.
3. The success of IVF depends on the type of infertility, with male factor infertility seeing live birth rates around 40% and female factor infertility around 25%, higher than other causes of infertility.
Threatened Miscarriage Verdict is out on Hormonal Treatment Dr Jyoti AgarwalLifecare Centre
- Threatened miscarriage occurs in around 15% of clinically recognized pregnancies and can cause significant emotional and psychological stress for couples.
- Multiple meta-analyses and randomized controlled trials have found that oral administration of dydrogesterone is more effective at reducing the risk of miscarriage in cases of threatened miscarriage compared to vaginal progesterone or no treatment.
- Dydrogesterone has higher bioavailability when taken orally compared to micronized progesterone, requires a lower dose, and may have immunomodulatory properties that further reduce the risk of miscarriage.
This document discusses treatment for miscarriages and the role of progestagens. It defines miscarriage and notes that it affects 1 in 4 pregnancies. Progestagens like progesterone help maintain pregnancy by enhancing implantation and preventing contractions. Studies on progestagen for threatened miscarriage show reduced miscarriage risk but results need cautious interpretation due to study limitations. For recurrent miscarriage, expert bodies do not currently recommend progestagens due to lack of long-term safety data, but ongoing trials like PRISM and PROMISE aim to provide further evidence on efficacy and safety.
IUI is a basic but effective form of fertiltiy treatment and can be a viable alternative to the expensive IVF / test tube baby treatment that is normally advised.
This presentation will be very useful for the practising gynecologists, IVF specialists and General practitioners who perform IUI.
Even patients on going through this presentation will be more educated about iui.
Please reach out to me on 9833032120 by whatsapp / Telegram or phone call or email on dalalsj@gmail.com for further details / treatment options.
Progesterone plays an important role in pregnancy. While progesterone supplementation may reduce miscarriage rates in women with threatened miscarriage or recurrent miscarriage, evidence is still preliminary. The PROMISE trial found no significant difference in live birth rates between progesterone and placebo in women with unexplained recurrent miscarriage. Guidelines provide consensus recommendations but state evidence is still limited. Progesterone appears safe with no significant adverse maternal or fetal effects reported. Further research is still needed to define optimal formulations, doses and durations of progesterone supplementation.
Optimizing The outcome of Threatened Abortion Dr Sharda Jain Lifecare Centre
- Around 70% of conceptions are lost prior to live birth, with 30% lost before implantation and 30% after implantation but before a missed period. Threatened abortion refers to vaginal bleeding or pain, or both, in early pregnancy when the cervical os remains closed.
- Studies have shown that counseling reduces adverse psychological effects from miscarriage. Treatment with dydrogesterone has been shown to reduce pregnancy loss in threatened abortion during the first trimester compared to placebo or no treatment. However, treatment with vaginal progesterone compared to placebo appears to have little effect on reducing miscarriage rates.
- Meta-analyses of multiple randomized controlled trials found that treatment with dydrogesterone for threatened miscarriage significantly reduced miscarriage
Is there a place for progesterone in the management of miscarriage?drmattprior
Miscarriage is the commonest complication in pregnancy. One in four pregnancies ends this way. The physical experience can be awful in itself, but in the words of a patient, "the grief of miscarriage can last forever."
The commonest question for women who have experienced miscarriage is simple--why did it happen? The answer is rarely apparent.
Many so-called "treatments" to prevent miscarriage are unproven. But recent research suggests some miscarriages may be prevented with progesterone.
In this talk for clinicians, I explored the most recent evidence.
1. The document discusses new concepts in infertility including updated WHO reference values for semen analysis, the use of ICSI for male factor infertility, and success rates varying based on the cause of infertility.
2. ICSI, where surgically retrieved sperm are injected into eggs, has become an established procedure for couples with male subfertility to have a biological child, with reassuring post-natal outcomes reported so far.
3. The success of IVF depends on the type of infertility, with male factor infertility seeing live birth rates around 40% and female factor infertility around 25%, higher than other causes of infertility.
Threatened Miscarriage Verdict is out on Hormonal Treatment Dr Jyoti AgarwalLifecare Centre
- Threatened miscarriage occurs in around 15% of clinically recognized pregnancies and can cause significant emotional and psychological stress for couples.
- Multiple meta-analyses and randomized controlled trials have found that oral administration of dydrogesterone is more effective at reducing the risk of miscarriage in cases of threatened miscarriage compared to vaginal progesterone or no treatment.
- Dydrogesterone has higher bioavailability when taken orally compared to micronized progesterone, requires a lower dose, and may have immunomodulatory properties that further reduce the risk of miscarriage.
This document discusses treatment for miscarriages and the role of progestagens. It defines miscarriage and notes that it affects 1 in 4 pregnancies. Progestagens like progesterone help maintain pregnancy by enhancing implantation and preventing contractions. Studies on progestagen for threatened miscarriage show reduced miscarriage risk but results need cautious interpretation due to study limitations. For recurrent miscarriage, expert bodies do not currently recommend progestagens due to lack of long-term safety data, but ongoing trials like PRISM and PROMISE aim to provide further evidence on efficacy and safety.
IUI is a basic but effective form of fertiltiy treatment and can be a viable alternative to the expensive IVF / test tube baby treatment that is normally advised.
This presentation will be very useful for the practising gynecologists, IVF specialists and General practitioners who perform IUI.
Even patients on going through this presentation will be more educated about iui.
Please reach out to me on 9833032120 by whatsapp / Telegram or phone call or email on dalalsj@gmail.com for further details / treatment options.
Progesterone plays an important role in pregnancy. While progesterone supplementation may reduce miscarriage rates in women with threatened miscarriage or recurrent miscarriage, evidence is still preliminary. The PROMISE trial found no significant difference in live birth rates between progesterone and placebo in women with unexplained recurrent miscarriage. Guidelines provide consensus recommendations but state evidence is still limited. Progesterone appears safe with no significant adverse maternal or fetal effects reported. Further research is still needed to define optimal formulations, doses and durations of progesterone supplementation.
Optimizing The outcome of Threatened Abortion Dr Sharda Jain Lifecare Centre
- Around 70% of conceptions are lost prior to live birth, with 30% lost before implantation and 30% after implantation but before a missed period. Threatened abortion refers to vaginal bleeding or pain, or both, in early pregnancy when the cervical os remains closed.
- Studies have shown that counseling reduces adverse psychological effects from miscarriage. Treatment with dydrogesterone has been shown to reduce pregnancy loss in threatened abortion during the first trimester compared to placebo or no treatment. However, treatment with vaginal progesterone compared to placebo appears to have little effect on reducing miscarriage rates.
- Meta-analyses of multiple randomized controlled trials found that treatment with dydrogesterone for threatened miscarriage significantly reduced miscarriage
Is there a place for progesterone in the management of miscarriage?drmattprior
Miscarriage is the commonest complication in pregnancy. One in four pregnancies ends this way. The physical experience can be awful in itself, but in the words of a patient, "the grief of miscarriage can last forever."
The commonest question for women who have experienced miscarriage is simple--why did it happen? The answer is rarely apparent.
Many so-called "treatments" to prevent miscarriage are unproven. But recent research suggests some miscarriages may be prevented with progesterone.
In this talk for clinicians, I explored the most recent evidence.
This document summarizes the role of progesterone in different contexts. It discusses how progesterone prepares the endometrium for implantation and supports early pregnancy. It reviews evidence from meta-analyses and clinical trials on the use of progesterone to prevent miscarriage in women with recurrent miscarriage, finding a beneficial effect. The document also examines evidence related to progesterone supplementation for luteal phase support in IVF cycles and for treating threatened abortion, finding current evidence is limited and more research is still needed.
This document summarizes evidence on the use of progesterone to prevent preterm birth. It finds that progesterone reduces the risk of preterm birth before 37 weeks in women with a prior preterm delivery or short cervix. Progesterone may also reduce complications for infants born preterm to mothers receiving it. However, progesterone does not prevent early preterm birth in twin or triplet pregnancies. No long-term harms were seen in children exposed to progesterone prenatally.
Dr Sujoy Dasgupta was invited to deliver a lecture at BOGSCON (The Annual Conference of Bengal Obstetric and Gynaecological Society) held at Kolkata in December 2019
Role of Dydrogesterone in Recurrent Pregnancy Loss Dr Sharda Jain Lifecare Centre
Dydrogesterone is commonly used by Indian gynecologists to treat recurrent pregnancy loss. It has higher bioavailability than natural micronized progesterone when taken orally. Dydrogesterone has an immunomodulatory effect that may help prevent miscarriage by inhibiting pro-inflammatory cytokines and increasing anti-inflammatory cytokines and progesterone-induced blocking factor production. It also increases uterine and endometrial blood flow by stimulating nitric oxide production. Several studies and meta-analyses indicate dydrogesterone may be more effective than natural micronized progesterone for treating recurrent pregnancy loss when taken orally, due to its higher bioavailability and specific affinity for progesterone receptors.
1. The document discusses measuring progesterone levels during IVF treatment and the role of progesterone in implantation.
2. There is debate around what progesterone levels indicate successful implantation, with some studies finding levels above 1.0 or 1.5 ng/ml can negatively impact outcomes, while others find higher thresholds.
3. Accurately measuring progesterone is challenging due to issues with assays, sample handling, and lack of standards between clinics. Establishing a standardized reference level could help improve IVF success rates.
This document discusses the role of progesterone in pregnancy and preventing preterm birth. It begins by outlining the problem of preterm birth globally, noting that 15 million babies are born preterm each year. It then discusses various trials investigating the use of progesterone supplementation to prevent preterm birth, including the large NICHD/MFMU trial which found that weekly injections of 17α-hydroxyprogesterone caproate reduced preterm birth rates. The document also notes vaginal progesterone trials have shown benefits but results are more mixed in high-order multiples and women with a short cervix may benefit most.
Role of Dydrogesterone in Threatened Abortion Dr Sharda Jain Lifecare Centre
*EXPERINCE SHARING By EXPERTS*
Dr Uma Rai(DGF *E*)
Dr Sangeetaa Gupta(DGF *E*)
Dr Neerja Varshney(DGF *E*)
Dr Surjeet Kapoor(DGF *E*)
Dr Rupam arora(DGF *E*)
Dr Meenakshi Ahuja(DGF *S* )
Dr.Harsha khullar(DGF *C* )
Dr Mamta mittal(DGF *N*)
Dr Leena Sreedhar(DGF *D*)
Dr.Dipti Nabh(DGF *E*)
Dr. Shama Batra(DGF *E*)
Dr Poonam Paul(DGF *SW*)
PAN DGF ( DELHI GYNAECOLOGIST FORUM) CME ON DYDROGESTERONE ON 3/2 /22
Clomiphene update in infertility Dr. Sharda Jain , Dr. Jyoti Agarwal Lifecare...Lifecare Centre
This document discusses clomiphene citrate (CC), a drug commonly used to induce ovulation. It begins by outlining the major causes of female infertility and notes that CC is the most commonly used drug for ovulation induction. The document then discusses the specifics of CC, noting that it is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene is identified as the isomer responsible for ovulation induction effects, while zuclomiphene can have negative effects like thinning of the endometrium. Studies show that enclomiphene alone at lower doses can have comparable ovulation induction effects to standard CC doses but without the potential side effects of zuclomip
Progesterone for luteal phase support in IVF cyclesHesham Al-Inany
Luteal phase support is essential for IVF cycles. Progesterone has many forms and modalities: which to use? this talk is an attempt to answer this question
LNG IUSROLE IN AUB DR. JYOTI BHASKAR Dr Sharda Jain Lifecare Centre
The document discusses the use of the levonorgestrel intrauterine system (LNG IUS) in the treatment of abnormal uterine bleeding (AUB). It provides details on the pharmacokinetics and mechanisms of action of LNG IUS in reducing bleeding. The summary discusses evidence that LNG IUS is more effective than other medical therapies in reducing bleeding, improves quality of life, and has high patient satisfaction. It is an appropriate first-line treatment for many causes of AUB and provides an effective long-acting reversible contraceptive option.
Gastrointestinal Complications in Pregnancy Dr Sharda Jain Lifecare Centre
Nausea and vomiting are common in early pregnancy, affecting 85% of women. Symptoms typically appear between 4-9 weeks and are most severe at 7-12 weeks, subsiding by 12-16 weeks for most. For 15% of women, symptoms continue until 20 weeks. Hyperemesis gravidarum is a more severe form involving weight loss, dehydration and electrolyte imbalance. Treatment involves dietary changes, ginger, vitamin B6, antihistamines and other drugs. For severe cases, hydration and other inpatient management may be needed.
The document discusses progestogens, which include progesterone and synthetic progestins. Progesterone is secreted naturally, while progestins have progesterone-like effects. Both are used for obstetric and gynecologic purposes. Therapeutically, progestogens are used to support early pregnancy, treat menstrual disorders, provide luteal phase support in assisted reproduction, and relieve symptoms of conditions like endometriosis. While generally effective, studies on uses like threatened miscarriage and preterm labor have been limited by small sample sizes. Natural progesterone generally has fewer side effects than progestins. The document examines various progestogen types and routes of administration.
This document discusses luteal phase support in assisted reproductive technology (ART) and recurrent miscarriages. It defines luteal phase defect (LPD) and notes there is no standardized diagnostic test. LPD can cause infertility and recurrent pregnancy loss. Progesterone supplementation is recommended for confirmed LPD, unexplained infertility, advanced maternal age, ART cycles, hyperprolactinemia, and recurrent miscarriages. Progesterone is the preferred drug for luteal phase support as it promotes endometrial development without luteolytic effects. Vaginal progesterone is as effective as intramuscular with fewer side effects and optimal timing and duration of support is from oocyte retrieval/IUI to 9 weeks of gestation.
Role of progesterone in rpl by dr alka mukherjee dr apurva mukherjeealka mukherjee
It is well known that progesterone plays a major role in the maintenance of pregnancy, particularly during the early stages, as it is responsible for preparing the endometrium for implantation and maintenance of the gestational sac. The management of pregnant women at risk of a threatened or idiopathic recurrent miscarriage is complex and critical.
Early pregnancy loss, also known as miscarriage, generally occurs in the first trimester. For some women and their partners, miscarriages can happen several times, also known as recurrent miscarriages. While there are sometimes causes for miscarriages that are found, often no clear reasons can be found. The hormone called progesterone prepares the womb (uterus) to receive and support the newly fertilized egg during the early part of pregnancy. It has been suggested that some women who miscarry may not make enough progesterone in the early part of pregnancy. Supplementing these women with medications that act like progesterone (these are called progestogens) has been suggested as a possible way to prevent recurrent miscarriage.
It describes the Progesterone physiology. It describes the latest evidence as regards progesterone formulations, use of progesterone as Luteal phase support. It scrutinizes the value of serum progesterone in monitoring luteal phase
The document discusses unexplained infertility, providing definitions and discussing prevalence, causes, diagnosis, and treatment options. It notes that unexplained infertility affects 10-20% of couples and can cause psychological distress. Potential causes are discussed but many are uncertain and found in fertile couples. Diagnosis involves ruling out known causes through standard investigations. Treatment aims to increase monthly pregnancy rates and options discussed include expectant management, ovulation induction, IUI, IVF, and alternative therapies like letrozole, with success rates provided for each option.
This document discusses endometriosis and its impact on fertility and IVF outcomes. It provides information on diagnosing and treating endometriosis, including:
- Laparoscopy is the gold standard for diagnosing endometriosis. Surgical excision of endometriomas and deep endometriosis can improve pain and fertility outcomes.
- For subfertility, treatment depends on factors like disease severity, pain levels, and reproductive plans. IVF is an option if conservative treatments fail.
- Studies show endometriosis may reduce ovarian response and increase IVF cancellation rates. However, it does not significantly impact live birth, pregnancy, or miscarriage rates compared to other infertility factors
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain Lifecare Centre
Update (2021) Oral Contraceptive Pill : Dr Sharda Jain
7 Billion 2011 & increasing a rate of 150 million per year
INDIA
Today – 1.3 billion 2050 – 1.628 expected
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
This document summarizes the role of progesterone in different contexts. It discusses how progesterone prepares the endometrium for implantation and supports early pregnancy. It reviews evidence from meta-analyses and clinical trials on the use of progesterone to prevent miscarriage in women with recurrent miscarriage, finding a beneficial effect. The document also examines evidence related to progesterone supplementation for luteal phase support in IVF cycles and for treating threatened abortion, finding current evidence is limited and more research is still needed.
This document summarizes evidence on the use of progesterone to prevent preterm birth. It finds that progesterone reduces the risk of preterm birth before 37 weeks in women with a prior preterm delivery or short cervix. Progesterone may also reduce complications for infants born preterm to mothers receiving it. However, progesterone does not prevent early preterm birth in twin or triplet pregnancies. No long-term harms were seen in children exposed to progesterone prenatally.
Dr Sujoy Dasgupta was invited to deliver a lecture at BOGSCON (The Annual Conference of Bengal Obstetric and Gynaecological Society) held at Kolkata in December 2019
Role of Dydrogesterone in Recurrent Pregnancy Loss Dr Sharda Jain Lifecare Centre
Dydrogesterone is commonly used by Indian gynecologists to treat recurrent pregnancy loss. It has higher bioavailability than natural micronized progesterone when taken orally. Dydrogesterone has an immunomodulatory effect that may help prevent miscarriage by inhibiting pro-inflammatory cytokines and increasing anti-inflammatory cytokines and progesterone-induced blocking factor production. It also increases uterine and endometrial blood flow by stimulating nitric oxide production. Several studies and meta-analyses indicate dydrogesterone may be more effective than natural micronized progesterone for treating recurrent pregnancy loss when taken orally, due to its higher bioavailability and specific affinity for progesterone receptors.
1. The document discusses measuring progesterone levels during IVF treatment and the role of progesterone in implantation.
2. There is debate around what progesterone levels indicate successful implantation, with some studies finding levels above 1.0 or 1.5 ng/ml can negatively impact outcomes, while others find higher thresholds.
3. Accurately measuring progesterone is challenging due to issues with assays, sample handling, and lack of standards between clinics. Establishing a standardized reference level could help improve IVF success rates.
This document discusses the role of progesterone in pregnancy and preventing preterm birth. It begins by outlining the problem of preterm birth globally, noting that 15 million babies are born preterm each year. It then discusses various trials investigating the use of progesterone supplementation to prevent preterm birth, including the large NICHD/MFMU trial which found that weekly injections of 17α-hydroxyprogesterone caproate reduced preterm birth rates. The document also notes vaginal progesterone trials have shown benefits but results are more mixed in high-order multiples and women with a short cervix may benefit most.
Role of Dydrogesterone in Threatened Abortion Dr Sharda Jain Lifecare Centre
*EXPERINCE SHARING By EXPERTS*
Dr Uma Rai(DGF *E*)
Dr Sangeetaa Gupta(DGF *E*)
Dr Neerja Varshney(DGF *E*)
Dr Surjeet Kapoor(DGF *E*)
Dr Rupam arora(DGF *E*)
Dr Meenakshi Ahuja(DGF *S* )
Dr.Harsha khullar(DGF *C* )
Dr Mamta mittal(DGF *N*)
Dr Leena Sreedhar(DGF *D*)
Dr.Dipti Nabh(DGF *E*)
Dr. Shama Batra(DGF *E*)
Dr Poonam Paul(DGF *SW*)
PAN DGF ( DELHI GYNAECOLOGIST FORUM) CME ON DYDROGESTERONE ON 3/2 /22
Clomiphene update in infertility Dr. Sharda Jain , Dr. Jyoti Agarwal Lifecare...Lifecare Centre
This document discusses clomiphene citrate (CC), a drug commonly used to induce ovulation. It begins by outlining the major causes of female infertility and notes that CC is the most commonly used drug for ovulation induction. The document then discusses the specifics of CC, noting that it is a mixture of two isomers, enclomiphene and zuclomiphene. Enclomiphene is identified as the isomer responsible for ovulation induction effects, while zuclomiphene can have negative effects like thinning of the endometrium. Studies show that enclomiphene alone at lower doses can have comparable ovulation induction effects to standard CC doses but without the potential side effects of zuclomip
Progesterone for luteal phase support in IVF cyclesHesham Al-Inany
Luteal phase support is essential for IVF cycles. Progesterone has many forms and modalities: which to use? this talk is an attempt to answer this question
LNG IUSROLE IN AUB DR. JYOTI BHASKAR Dr Sharda Jain Lifecare Centre
The document discusses the use of the levonorgestrel intrauterine system (LNG IUS) in the treatment of abnormal uterine bleeding (AUB). It provides details on the pharmacokinetics and mechanisms of action of LNG IUS in reducing bleeding. The summary discusses evidence that LNG IUS is more effective than other medical therapies in reducing bleeding, improves quality of life, and has high patient satisfaction. It is an appropriate first-line treatment for many causes of AUB and provides an effective long-acting reversible contraceptive option.
Gastrointestinal Complications in Pregnancy Dr Sharda Jain Lifecare Centre
Nausea and vomiting are common in early pregnancy, affecting 85% of women. Symptoms typically appear between 4-9 weeks and are most severe at 7-12 weeks, subsiding by 12-16 weeks for most. For 15% of women, symptoms continue until 20 weeks. Hyperemesis gravidarum is a more severe form involving weight loss, dehydration and electrolyte imbalance. Treatment involves dietary changes, ginger, vitamin B6, antihistamines and other drugs. For severe cases, hydration and other inpatient management may be needed.
The document discusses progestogens, which include progesterone and synthetic progestins. Progesterone is secreted naturally, while progestins have progesterone-like effects. Both are used for obstetric and gynecologic purposes. Therapeutically, progestogens are used to support early pregnancy, treat menstrual disorders, provide luteal phase support in assisted reproduction, and relieve symptoms of conditions like endometriosis. While generally effective, studies on uses like threatened miscarriage and preterm labor have been limited by small sample sizes. Natural progesterone generally has fewer side effects than progestins. The document examines various progestogen types and routes of administration.
This document discusses luteal phase support in assisted reproductive technology (ART) and recurrent miscarriages. It defines luteal phase defect (LPD) and notes there is no standardized diagnostic test. LPD can cause infertility and recurrent pregnancy loss. Progesterone supplementation is recommended for confirmed LPD, unexplained infertility, advanced maternal age, ART cycles, hyperprolactinemia, and recurrent miscarriages. Progesterone is the preferred drug for luteal phase support as it promotes endometrial development without luteolytic effects. Vaginal progesterone is as effective as intramuscular with fewer side effects and optimal timing and duration of support is from oocyte retrieval/IUI to 9 weeks of gestation.
Role of progesterone in rpl by dr alka mukherjee dr apurva mukherjeealka mukherjee
It is well known that progesterone plays a major role in the maintenance of pregnancy, particularly during the early stages, as it is responsible for preparing the endometrium for implantation and maintenance of the gestational sac. The management of pregnant women at risk of a threatened or idiopathic recurrent miscarriage is complex and critical.
Early pregnancy loss, also known as miscarriage, generally occurs in the first trimester. For some women and their partners, miscarriages can happen several times, also known as recurrent miscarriages. While there are sometimes causes for miscarriages that are found, often no clear reasons can be found. The hormone called progesterone prepares the womb (uterus) to receive and support the newly fertilized egg during the early part of pregnancy. It has been suggested that some women who miscarry may not make enough progesterone in the early part of pregnancy. Supplementing these women with medications that act like progesterone (these are called progestogens) has been suggested as a possible way to prevent recurrent miscarriage.
It describes the Progesterone physiology. It describes the latest evidence as regards progesterone formulations, use of progesterone as Luteal phase support. It scrutinizes the value of serum progesterone in monitoring luteal phase
The document discusses unexplained infertility, providing definitions and discussing prevalence, causes, diagnosis, and treatment options. It notes that unexplained infertility affects 10-20% of couples and can cause psychological distress. Potential causes are discussed but many are uncertain and found in fertile couples. Diagnosis involves ruling out known causes through standard investigations. Treatment aims to increase monthly pregnancy rates and options discussed include expectant management, ovulation induction, IUI, IVF, and alternative therapies like letrozole, with success rates provided for each option.
This document discusses endometriosis and its impact on fertility and IVF outcomes. It provides information on diagnosing and treating endometriosis, including:
- Laparoscopy is the gold standard for diagnosing endometriosis. Surgical excision of endometriomas and deep endometriosis can improve pain and fertility outcomes.
- For subfertility, treatment depends on factors like disease severity, pain levels, and reproductive plans. IVF is an option if conservative treatments fail.
- Studies show endometriosis may reduce ovarian response and increase IVF cancellation rates. However, it does not significantly impact live birth, pregnancy, or miscarriage rates compared to other infertility factors
Update (2021) Oral Contraceptive Pill : Dr. Jyoti Agarwal Dr Sharda Jain Lifecare Centre
Update (2021) Oral Contraceptive Pill : Dr Sharda Jain
7 Billion 2011 & increasing a rate of 150 million per year
INDIA
Today – 1.3 billion 2050 – 1.628 expected
Role of progestogens in obstetrics and gynecologyAhmad Saber
The
different progestogens with their overlapping effects on estrogen, androgen, glucocorticoid,
and mineralocorticoid receptors are described in order to allow the clinician to make the most appropriate choice of progestogen.
Uterine Fibroids: Symptoms, Causes, Risk Factors & Treatment uterine fibroids aren't associated with an increased risk of uterine cancer and almost never develop into cancer
Dienogest+ Ethinyl Estradiol Role in oral contraception & Acne Dr Sharda Jain...Lifecare Centre
Dienogest + Ethinyl Estradiol is a combination oral contraceptive pill that provides contraception and treats mild to moderate acne. It contains the 4th generation progestin Dienogest and the estrogen Ethinyl Estradiol. Dienogest has anti-androgenic properties and does not have the side effects seen with other progestins like weight gain, acne, or changes in lipids. It works primarily by suppressing gonadotropins to inhibit ovulation and by changing cervical mucus to block sperm entry. Clinical trials demonstrate it is effective contraception with fewer side effects than other pills.
This document provides an overview of estrogens, progestins, and androgens. It discusses their synthesis, physiological effects, regulation, and therapeutic formulations and uses. Estrogens are involved in reproductive functions and non-reproductive tissues. Progestins are used in contraceptives and hormone replacement therapy. Androgens have roles in reproduction and behavior. Oral contraceptives contain estrogen and progestin combinations to suppress ovulation and prevent pregnancy.
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...Lifecare Centre
Letrozole is an aromatase inhibitor that has been shown to be effective for ovulation induction. It works by decreasing estrogen production in the ovaries. Some advantages of letrozole over clomiphene citrate include shorter half-life, lack of anti-estrogenic effects on the endometrium and cervical mucus, increased uterine blood flow, and lower risks of multiple pregnancy and OHSS. Common side effects include hot flashes and headaches. Guidelines from several medical societies recommend letrozole as a first-line treatment for ovulation induction in women with PCOS. The starting dose is typically 2.5 mg daily for 5 days, but step-up protocols have also shown effectiveness.
This document provides information about oral contraceptives. It discusses the types of oral contraceptives including combination pills (monophasic, biphasic, triphasic), progestin pills, and morning after pills. Combination pills contain both estrogen and progesterone while progestin pills only contain progesterone. The document explains the mode of action of oral contraceptives by suppressing LH and FSH to inhibit ovulation. Potential side effects are also outlined such as nausea, headaches, and weight gain. In summary, this document reviews the different types of oral contraceptive pills, their mode of action in preventing pregnancy, and possible adverse effects.
A slight description on contraception, its types along with a brief explanation on Oral Contraceptives. Types of oral contraceptives, it's types, mechanism of action, contraindications, dosing, advantages, disadvantages, risk, benefit amd recent research trends.
This document discusses medical management options for dysfunctional uterine bleeding (DUB). It begins by defining DUB and outlining treatment goals of controlling bleeding, correcting related conditions, preventing recurrence, and improving quality of life. First line treatment is recommended to be a levonorgestrel-releasing intrauterine system. Other options discussed include tranexamic acid, NSAIDs, combined oral contraceptives, and various progestogen therapies. Ormeloxifene is presented as an ideal selective estrogen receptor modulator for DUB due to its tissue-specific effects and safety profile. Studies demonstrate its effectiveness in reducing bleeding and improving outcomes for women with DUB.
This document discusses menopausal hormone therapy (MHT), also known as hormone therapy (HT). It defines key terms and outlines the history and background of MHT, including findings from the Women's Health Initiative trial in the late 1990s that raised safety concerns and led to a decline in MHT use. The document discusses guidelines for evaluating candidates for MHT and outlines potential benefits and risks to consider for individual patients. It also provides tables listing FDA-approved MHT drug products available in the US, including oral, transdermal, and vaginal estrogen therapies alone or in combination with progestogens.
A benign tumor of muscular and fibrous tissues, typically developing in the wall of the uterus.
Prevalence varies among studies and countries (4.5-68.6%)
Nearly 20-30% Indian women in reproductive age group have fibroid uterus
At any given time, nearly 15-25 million Indian women have fibroid uterus
Understand fibroids in a better way
Dr. Sharda Jain, Dr. Jyoti Agarwal, and Dr. Jyoti Bhaskar presented an interactive session on the medical management of dysfunctional uterine bleeding (DUB) in 2014. Ormeloxifene, a selective estrogen receptor modulator, was discussed as a non-steroidal treatment option for DUB that has shown efficacy in several pilot studies and randomized controlled trials. Ormeloxifene has advantages of a convenient dosing schedule and few side effects, and has been used to successfully treat over 700 patients with DUB. Feedback was encouraged from participants on experiences treating DUB.
1. Aromatase inhibitors like letrozole are used to treat breast cancer and endometriosis by suppressing estrogen production.
2. Letrozole has been shown to effectively induce ovulation, with limited follicular development and no adverse effects on the endometrium. It achieves ovulation rates of 50-90% and pregnancy rates of 15-25% for conditions like PCOS and infertility.
3. When used as an adjunct to FSH for poor responders, letrozole lowers FSH doses and cycle cancellation rates while improving ovarian response and pregnancy rates compared to standard protocols.
This document describes various hormonal contraceptive options, including their mechanisms of action, effectiveness, side effects, and appropriate patients. It discusses oral contraceptives containing different estrogen and progestin combinations, the contraceptive patch, injectables, rings, implants, and IUDs. It provides details on the benefits and risks of each method as well as contraindications. Emerging extended cycle oral contraceptives and a new subcutaneous injectable are also mentioned.
Medical management of dub – new modalities dr. jyoti bhaskar lecture 4Lifecare Centre
This document discusses treatment options for dysfunctional uterine bleeding (DUB). It begins by defining heavy menstrual bleeding and noting the goals of treatment. It recommends a woman-centered approach. The NICE guidelines recommend levonorgestrel-releasing intrauterine system (LNG-IUS) as first-line treatment, followed by tranexamic acid or NSAIDs as second-line options. Third-line includes oral or injected progestogens. It also discusses the use of oral contraceptives, progestational agents like medroxyprogesterone acetate, and the potential role of selective estrogen receptor modulators like ormeloxifene. Surgical and medical management are compared.
Cr 013 presentation sporanox® by carolina hung hoCarolina Hung Ho
I created these slides for the course of CR 013 Pharmacology and Clinical Safety Assessments at AAPS. This purpose of this presentation is to choose an approved medication on the market and propose a new indication in another therapeutic area. I chose Sporanox from Janssen Pharmaceutica and proposed it for the treatment of cancer. Please, enjoy the slides.
This document discusses the management of erectile dysfunction. It provides an overview of various treatment considerations including lifestyle modifications, medication changes, psychosexual therapy, hormonal therapy, pharmacologic therapy, and medical devices or surgery. Pharmacologic therapies discussed in detail include phosphodiesterase type 5 inhibitors like sildenafil, tadalafil, and avanafil. Intracavernosal injection therapies using alprostadil, papaverine, and phentolamine are also covered. The document provides guidance on optimizing effects, precautions, side effects and considerations for various erectile dysfunction treatment options.
This document provides information on a peer group discussion about hormonal replacement therapy presented by Ms. Santosh Kumari. It defines HRT, describes the benefits which include relief of menopausal symptoms and reduction of osteoporosis risk. It also outlines the risks such as a small increased risk of breast cancer and cardiovascular disease. Different preparations of HRT are discussed and indications and contraindications provided.
Similar to Contraception, Hormones, Progestogens: Update : Dr. Jyoti agarwal Dr. Sharda Jain (20)
The Newer Concepts In Endometriosis Management : Dr Sharda JainLifecare Centre
The Newer Concepts In
Endometriosis Management
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DELEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
The Newer Concepts forReduced Surgery to preserve fertility in Endometrios...Lifecare Centre
The Newer Concepts forReduced Surgery to preserve fertility in Endometriosis
ENDOMETRIOSIS IS ENIGMA
DIAGNOSTIC DILEMMA
DEBILITATING DISEASE QOL
PROGRESSIVE DISEASE
RECURRENCE IS BIG PROBLEM
NO FINAL VERDICT ON CAUSE
NO PERMANENT CURE
The exact prevalence of endometriosis is unknown, but estimates 10% in the general female population in India but up to 50% in infertile women
Anemia Free India Gynaecologist to focuss on *12gm Haemoglobin at Delivery I...Lifecare Centre
Important Highlights
Prophylactic Iron and Folic Acid Supplementation in all six target age groups.
Intensified year-round Behaviour Change Communication (BCC) Campaign for:(a) improving compliance to IFA and deworming, (b) enhancing appropriate infant and young child feeding practices, (c) encouraging increase in intake of iron-rich food through diet and/or fortified foods (d) ensuring delayed cord clamping .
Testing and treatment of anaemia, using digital methods and point of care treatment, with special focus on pregnant women and school-going adolescents.
Addressing non-nutritional causes of anaemia
in endemic pockets with special focus on malaria, hemoglobinopathies and fluorosis
Liver Dialogue for Gynaecologists : Dr Sharda JainLifecare Centre
This document discusses the functions of the liver and various liver function tests. It notes that the liver has important metabolic, excretory, protective, hematological, synthetic and storage functions. It then describes several common liver function tests including SGPT, SGOT, GGT, ALP, bilirubin, total protein, albumin, PT, bleeding time and clotting time. It provides details on the clinical significance, normal ranges and potential causes of interference for each of these tests. The document emphasizes that liver function tests can help screen for and diagnose liver dysfunction, assess prognosis, and monitor response to therapy.
National Tuberculosis elimination programme (NIKSHAY)Big Challenge to GOI : ...Lifecare Centre
India has a high tuberculosis (TB) burden, accounting for approximately 50% of global cases. The Government of India's National Tuberculosis Elimination Program (NTEP) aims to eliminate TB in India by 2025 through programs like NIKSHAY and NIKSHAY MITRA SCHEME. However, India faces significant challenges to eliminating TB, including delays in diagnosis, drug-resistant strains, poor treatment adherence, stigma, comorbidity with HIV/AIDS, weaknesses in healthcare infrastructure, and social determinants like poverty and overcrowding. Overcoming these challenges will require sustained political will, funding, and strengthened surveillance and monitoring systems.
This document discusses innovations and breakthroughs in in vitro fertilization (IVF). It covers the following topics in 3 sentences or less:
Genetic screening techniques like preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS) are discussed to select embryos without genetic disorders or the highest chance of implantation. Time-lapse monitoring is presented as a way to continuously monitor embryo development in real-time without disruptions. Stem cell therapy and its potential role in inducing ovarian regeneration and sustained ovarian function is briefly covered.
Strategies for Improving Success Rates in ART PARTLifecare Centre
Strategies for Improving Success Rates in ART
Part - 2
Strategies for Improving Success Rates in ART
Tailoring Controlled Ovarian Stimulation
Strategies for Luteal Phase in ART cycles
Endometrial Receptivity Array
20 Simple ways for the Indian public to save water on World Water Day : Dr Sh...Lifecare Centre
Simple ways for the Indian public to save water on World Water Day include fixing leaks, installing faucet aerators to reduce water flow, and taking shorter showers. Other tips are to turn off taps when not in use, collect rainwater, and reuse greywater from washing for gardening. People should also use buckets instead of hoses for tasks like washing vehicles and water plants wisely to minimize evaporation.
Vaccination during Pregnancy & its Importance : Dr Sharda JainLifecare Centre
This document discusses the importance of vaccination during pregnancy. Some key points:
- Global and national health authorities recommend vaccines for influenza, tetanus, diphtheria, and pertussis during pregnancy to protect both mother and baby. Maternal immunization provides passive immunity to newborns.
- Pregnant women and young infants are especially vulnerable to certain infections. Vaccination of mothers during pregnancy is the most effective strategy to protect newborns who are too young for certain vaccines.
- Clinical trials have shown vaccines such as the Tdap and influenza vaccines to be generally safe and effective for pregnant women and their infants. Maternal immunization has significantly reduced disease in newborns for illnesses like
How to optimize success rates in ART? : Dr Sharda JainLifecare Centre
How to optimize success rates in ART? : Dr Sharda Jain
How to improve success rates in ART?
The big debate कार्य में आनंद
Evolution of In-vitro Fertilization (IVF)
Factors Influencing IVF Success Ist Part
Strategies for Improving Success Rates in ART Second Part
Innovations & Breakthroughs in IVF Part Three
OPEN DEBATE
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda JainLifecare Centre
SOCIALEGG FREEZING : Dr Poorva Bhargav and Dr Sharda Jain
Introduction
Social egg freezing (oocyte cryopreservation for non-medical reasons) has evolved as a proactive option for women looking to extend their reproductive possibilities past their peak childbearing years
It is the process of saving or protecting eggs, or reproductive tissues so that a person can use them to have biological children in future
White Coat Hypertension During Pregnancy : Dr Sharda JainLifecare Centre
During pregnancy, white coat hypertension has an average prevalence of 15% to 30%. While 60-70% of detected cases of white coat hypertension actually have true gestational hypertension or pre-existing essential hypertension that require monitoring and treatment. Choices of anti-hypertension medication during pregnancy need to be considered carefully.
White Coat hypertension Why it is Important? : Dr Sharda JainLifecare Centre
This document outlines an epidemiology and definitions presentation on hypertension. It discusses types of hypertension like white coat hypertension, where anxiety in a medical environment causes abnormally high readings. Isolated systolic hypertension is also covered, noting that systolic blood pressure is a more important risk factor after age 50. Statistics are provided on hypertension being a major cause of premature death worldwide and its prevalence in India. The summary concludes that white coat hypertension has a prevalence of 20-35% and is associated with minimal increased risk, though 60-70% of cases ultimately have true hypertension requiring treatment and monitoring.
Know Your Blood Pressure Understanding Blood Pressure Reading : Dr Sharda JainLifecare Centre
Hypertension, or high blood pressure, affects over a quarter of the global adult population. A blood pressure reading contains two numbers that indicate systolic and diastolic pressure. There are different types of hypertension including primary or essential hypertension and secondary hypertension caused by an underlying medical condition.
This document provides an overview of stillbirths including definitions, epidemiology, etiology, approaches to management of stillbirth cases and subsequent pregnancies. It notes that the stillbirth rate in India in 2021 was 12.4 per 1000 births. Investigating the causes of stillbirth involves examining the mother, fetus, placenta and membranes through history, examinations, tests and potentially an autopsy. Managing subsequent pregnancies after a stillbirth includes increased surveillance and optimizing any medical conditions to reduce recurrence risks. The aim is to reduce India's stillbirth rate to 10 per 1000 births by 2030.
IRON DEFICIENCY ANEMIA OVERVIEW WITH FOCUS ON PARENTRAL IRON THERAPY : Dr ...Lifecare Centre
This document provides an overview of iron deficiency anemia with a focus on parental iron therapy. Some key points:
- Iron deficiency anemia affects around 2 billion people globally and has a prevalence of 50.1% among pregnant women in India.
- Parenteral iron therapies like ferric carboxymaltose are recommended for pregnant women who are anemic late in pregnancy or those with low compliance to oral iron due to the ability to deliver a complete replacement dose in a single infusion.
- Ferric carboxymaltose has advantages over earlier parenteral iron formulations as it is a robust carbohydrate-iron complex that allows for higher dosing, has a shorter infusion time, and has a
CHECK LIST FOR ART SPECIALIST BEFORE IVF-ICSI FOR PATIENTS SEEKING IVF -ICSI ...Lifecare Centre
The document provides a checklist for an ART specialist to follow before performing IVF-ICSI treatment for patients. It outlines several areas to evaluate including conducting medical evaluations of both partners, assessing fertility through testing, providing psychological evaluation and counseling, reviewing lifestyle factors and making modifications, ensuring vaccinations are up to date, screening for infections, considering genetic testing, providing preconception care, discussing financial aspects and consent forms, explaining the ovarian stimulation and embryo transfer processes, and scheduling follow up appointments. The specialist should tailor the checklist to each patient's specific needs and circumstances and provide clear communication and support throughout the IVF-ICSI process.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...Université de Montréal
“Psychiatry and the Humanities”: An Innovative Course at the University of Montreal Expanding the medical model to embrace the humanities. Link: https://www.psychiatrictimes.com/view/-psychiatry-and-the-humanities-an-innovative-course-at-the-university-of-montreal
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
This presentation gives information on the pharmacology of Prostaglandins, Thromboxanes and Leukotrienes i.e. Eicosanoids. Eicosanoids are signaling molecules derived from polyunsaturated fatty acids like arachidonic acid. They are involved in complex control over inflammation, immunity, and the central nervous system. Eicosanoids are synthesized through the enzymatic oxidation of fatty acids by cyclooxygenase and lipoxygenase enzymes. They have short half-lives and act locally through autocrine and paracrine signaling.
7. Combined Oral Contraceptives ( COC )
Commonly known as “Pill”
• Widely Accepted & Most Effective
Reversible method of Fertility Control
• In 1951, India was the 1st country in world to
introduce COC in National programme of Family
Planning
8. The type of birth control to use is the personal
decision but experts feel if you are sexually
active & do not want to have pregnancy you
should consider birth control pills
as they are very effective
9. Oral Hormonal contraception
• In the 1940s, the American chemist Dr Russell Marker
discovered that some plants contained hormone-like
substances and he began purifying progesterone from
Mexican yams.
• However, progesterone is broken down in the digestive
tract and is not absorbed
• In the 1950s, synthetic versions of the hormone were
developed, known as progestogens
• The first large trial of the combined oral
contraceptive (COC) pill took place in Puerto Rico in
1956
Carol A Quarini, History of contraception, Women's Health Medicine, Volume 2, Issue 5, September–October 2005, Pages 28–30
10.
11. As per Speroff…..
The estrogen content of the pill is of major clinical
importance.
Thrombosis is one of the most serious side effects of the pill,
playing a key role in the increased risk of death (in the past
with high doses) from a variety of circulatory problems.
This side effect is related to estrogen, and it is dose related.
Therefore, the dose of estrogen is a critical issue in selecting
an oral contraceptive.
12. Doses of estrogen have been steadily reduced,
From 150 mcg mestranol (equivalent to 100 mcg EE)
To the COCs of today, which contain </=35 mcg EE
150mcg Mestranol (=100mcg EE)2
50mcg EE
35mcg EE
30mcg EE
20mcg EE
Estrogen component of COCs
functions primarily to provide
stable and predictable cycle
control,
Higher doses of estrogen is
associated with adverse events,
such as nausea, breast tenderness
and bloating
13. As compared to women using 20 mcg preparations, those using the 35 mcg consistently
experienced considerably more frequent estrogenic side effects
This study suggests that 20 mcg OC represent a logical and beneficial doses
0
0.5
1
1.5
2
Nausea
Breast
tenderness
Bloating
Ratio of COC-related symptoms with 35 micrograms of
ethinyl estradiol (EE) relative to 20 micrograms
Relative
risk
ratio
*
*
*
Study Design: Randomized, open-
label multicenter clinical trial
comparing OC Pill containing (20
mcg ethinyl estradiol [EE] with
levonorgestrel), (20 mcg EE with
desogestrel ), and (35 mcg EE with
norgestimate )463 OC starters or
switchers.
Result: Bloating, breast tenderness,
and nausea were approximately 50%
more common in women using 35
mg EE as compared to 20 mg EE
preparations.
95% CI,
1.29 -1.46
RR 1.4
95% CI,
1.44 -1.60
RR 1.5
95% CI,
1.37 -1.89
RR 1.6
P=0.000
P=0.000
P=0.004
Side effects of estrogen increased at higher dose
14. High-dose estrogen COCs linked to
macrovascular risk
0
0.5
1
1.5
2
2.5
3
3.5
Lidegaard Ø et al. BMJ 1993;306:956–963
Odds
ratio
Progestin
only
30–40 mcg
estrogen
50 mcg
estrogen
OC non-
users
Cerebral thromboembolic risk with oral
contraceptives according to estrogen content
OC=oral contraceptive
Study Design: A retrospective
case-control study to assess the risk
of cerebral thromboembolism in
794 women in Denmark aged 15-44
who had suffered a cerebral
thromboembolic attack during
1985-9 and 1588 age in control
matched randomly selected controls.
Result: Combined or sequential
pills containing 30-40 mcg
oestrogen are associated with a
one third reduced risk compared
with preparations containing 50
mcg estrogen.
16. Evolution of progestogens focused on reducing the
androgenic side effects
• Removal of the 19-carbon from ethisterone to form norethindrone did
not destroy the oral activity, and most importantly, it changed the major
hormonal effect from that of an androgen to that of a progestational
agent
• The new progestins, because of their reduced androgenicity, do not adversely
affect the cholesterol-lipoprotein profile
• Indeed, the estrogen-progestin balance of combined oral contraceptives
containing one of the new progestins even promote favorable lipid changes
• The androgenic properties of these compounds, however, were not totally
eliminated and minimal anabolic and androgenic potential remains within the
structure
17. The ability of any progestin to bind to the progesterone
receptor varies between different compounds and by this,
the biological effect of the progestin is influenced
Relative binding
affinity
Progesterone LNG 3-Keto-DSG DNG DRSP
Progesterone receptor 50 150 150 5 35
Androgen receptor 0 45 20 10 65
Estrogen receptor 0 0 0 0 0
Glucocorticoid
receptor
10 1 14 1 6
Mineralocorticoid
receptor
100 75 0 0 230
Binding affinity relative to: androgen receptor, metribolone=100%; estrogen receptor, estradiol 17=100%; glucocorticoid receptor,
dexamethasone=100%; mineralocorticoid receptor, aldosterone=100%
LNG: levonorgestrel; 3-Keto-DSG: active metabolite of desogestrel (DSG); DNG: dienogest; DRSP: drospirenone
High specificity for PR and low affinity for other
steroid receptors is a desirable attribute
18. Selectivity index
Selectivity index is simply obtained by dividing the progestogenic binding affinity of each compound
by its androgenic binding affinity, thus leading to a ratio of desired and undesired hormonal
properties.
High progestogenic
affinity
Low androgenic affinity
High
selectivity
Index
0
5
10
15
20
25
30
35
40
45
LNG
NET 3-keto-DSG GSD
RBAOrg 2058/ RBADHT
5
8.8
40*
26*
This slide confirms that third generation progestogens are more selective than the
older types and that within this group, 3-keto-desogestrel (which is the active
metabolite of desogestrel) is the most selective progestogen.
19. Desogestrel stands out due to its
remarkable characteristics
Deletion of oxygen molecule at position 3
Addition of methylene group at position 11
• Theoretical Effect
– Oxygen replaced in the liver leads to the active 3-Keto-DSG
– Methylene removes the androgenic side-effects
3
11
Levonorgestrel Molecule
Desogestrel Molecule
20. Evidence Summaries
Randomized
Controlled Double
Blind Studies
Cohort Studies
Case Control Studies
Case Series
Case Reports
Ideas, Editorials, Opinions
Systematic Reviews and Meta-analysis
Accessed on 16-8-12 at http://ebp.lib.uic.edu/applied_health/node/12
21. 13290 healthy, fertile women from
multiple centers
Ob/gyn: contraception
history, BMI, BP, skin
androgenic symptoms
(Desogestrel 150mcg +
Ethinylestradiol 30mcg) 21X7 regimen
Cycle 2
3
4
5
6
F/U of 11605 patients
Outcome:
•Reliability
•Cycle Control
•Side effects
Clinical Evaluation of a Monophasic Ethinylestradiol /
Desogestrel-containing Oral Contraceptive
Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinyl/desogestrel containing oral contraceptive. Arznei Forsch/Drug Res 1988; 38 (II): 932-4
Study Design
A multicenter trial was
conducted in 267 centers
in Italy to evaluate the
efficacy, acceptability and
safety of a monophasic
oral contraceptive
containing 30 μg ethinyl
estradiol and 150 μg
desogestrel
13,290 women were to be
followed up for a total of
74,967 cycles.
22. Results:
(N=11,605)
3
25
20
15
1
0
5
0
BTB
spotting
2
1
0 4 5 6
cycle
percentage
The incidence of irregular
bleeding returned to pre-
treatment levels by 3rd cycle
and decreased to 2.9% by 6th
cycle
Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinyl/desogestrel containing oral contraceptive. Arznei Forsch/Drug Res 1988; 38 (II): 932-4
Cycle control:
Efficacy:
•During the total of 74,967 evaluated
cycles only three pregnancies occurred.
•The Pearl Index is 0.0 for method failure
and 0.04 for patient failure.
Cycle Nausea Headache
Breast
tenderness
0 2.2 9.9 7.9
3 4.6 6.9 7.1
6 1.2 2.8 4.9
(Discontinuation rate for subjective side effects 2.3%)
Subjective side effects:
23. Conclusion
• The monophasic oral contraceptive containing 150 μg desogestrel and
30 μg ethinyl estradiol was shown to be very reliable.
• Cycle control was good: The incidence of irregular bleeding returned to
pre-treatment levels by 3rd cycle and decreased to 2.9% by 6th cycle
• The general incidence of minor complaints was lower than reported
before treatment commenced.
Bilotta P, Favilli S. Clinical evaluation of a monophasic ethinyl/desogestrel containing oral contraceptive. Arznei Forsch/Drug Res 1988; 38 (II): 932-4
24. Key
Trials
0.1
13290
Billota and Favilli et al
5.2
1690
Rekers et al
4.0
219
Van Trappen et al
2.9
1221
Walling et al*
5.8
208
Wiseman et al
6.0
475
Dieben et al
2.1
277
Lanchit and fixon et al*
BTB
%
Number
Trial
Irregular bleeding incidence in cycle 6
12 years of clinical experience with an Oral Contraceptive
Containing 30mcg Ethinyloestradiol and l50mcg Desogestrel reviewed using 14 clinical
trials.
• 14 Clinical Trials involving over 44,000
women for more than 1,90,000 cycles
• No pregnancies due to method failure
overall (PI- 0.12)
• Incidence of BTB- 0.1%-6.0%
• Incidence of subjective side effects
were low
• No significant change in hematological
and metabolic changes
• 2-3 fold in SHBG levels with fall in
testosterone levels
Fotherby.K. Contraception. 1995; 51:3-12
BTB = breakthrough bleeding and relates to % of subjects
except two trials marked' which relate to % of cycles. + =
data not given.
About 90% of subjects maintained regular cycles.
In all trials, the COC was well accepted and the rates of discontinuation were similar to
those in other COC trials.
25. Effect on Lipid profile
Desogestrel-ethinylestradiol,
an oral monophasic
contraceptive clinical and lipid
metabolic effects: A 5-year
experience (Open study)
n=311
(Reproductive age with proven fertility.
No hormonal preparation 3 months prior)
Group I (n=118)
DSG-EE group
Group II (n=134)
LNG-EE group
Group III (n=59)
NET-EE group
group I (n=59)
Monophasic
group II (n=75)
Triphasic
Outcome
Stopped at
40 cycles
Study Completed at 60 cycles
Start
To Group I (n=53)
n=49
Stopped
Material/Methods
Rubio-Lotvin et al, Adv Cont Deliv Syst vol 8;75-88
•Efficacy
•Cycle Control
•Blood Pressure
•Lipid Profile
Group I: 118 pt Desogestrel 150mcg +
Ethinylestradiol 30mcg (Monophasic)
•Group II: Levonorgestrel +Ethinylestradiol
pills:group I: Monophasic pill (150mcg
LNG+30mcg EE)
•group II: Triphasic pill
•Group III: Norethinderone 1mg +
Ethinylestradiol 35mcg (Monophasic)
26. Desogestrel-ethinylestradiol, an oral monophasic contraceptive
clinical and lipid metabolic effects: A 5-year experience
Parameters
and cycle
Group I Group II Group
III
Staining 4.5%* 10.3%** 6.5%***
Spotting 2.3% # 4.8% # # 3.5% # #
#
P<0.001
Breakthrough Bleeding:
Results: Body Weight:
Period Group I Group II Group III
Initial 62 Kg 67 Kg 65 Kg
At 60 cycles 88%
(63±0.6)
86%
(70±3.2)
85%
(66±1.6)
12%
(62±0.5)
10%
(69±2.2)
15%
(67±2.2)
--- 4%
(68±1.2)
---
P<0.001
Blood Pressure:
Rubio-Lotvin et al, Adv Cont Deliv Syst vol 8;75-88
*Cycle 4,5,7 **Cycle 2,4,7,8,10,12 ***Cycle 3,5,8
#Cycle 1,2,3,6 ##Cycle 1,3,8,10,11 ###Cycle 2,4,6,7
•In group I, there was an increase of 0.6 kg in 80% of
the women and a decrease of 0.5 kg in 12%. 8%
showed no change.
•In group II, there was an increase of 3.2 kg in 86% of
the women, 2.2 kg in 10% and 1.2 kg in 4%.
•In group lII, an increase of 1.6 kg in 85% and 2.2 kg in
15% was recorded
No significant effect on blood pressure
was seen in all the three groups
27. Lipid profile
HDL-c (%) Group I
Group II
(monophasic)
Group II
(triphasic) Group III
Normal HDL: 15-45%
HDLc Initial 27.7 26.6 28.9 29.9
HDLc after 40
cycles 36.8 20.3 22.5 27.2
27.7
26.6
28.9 29.9
36.8
20.3
22.5
27.2
0
5
10
15
20
25
30
35
40
Group I Group II
(monophasic)
Group II (triphasic) Group III
HDLc Initial
HDLc after
40 cycles
HDL changes:
Lipid Profile:
T.
Cholest
erol
(mg/dl) Group I
Group II
(Monophasic)
Group II
(Triphasic)
Grou
p III
Normal Value: 130-220 mg/dl
Initial 159.4 167 168.8 176.8
After 40
cycles 163.9 172.9 165.2 165.2
LDL
(%)
Group
I
Group II
(Monophasi
c)
Group II
(Triphasic)
Group
III
Normal LDL: 45-60%
Initial 47.4 55.6 54.9 49.9
After 40
cycles 46.6 56.7 54.7 52.1
There were no alterations of total
lipids and total cholesterol.
LDL-c did not show significant changes
At 40th week, subjects from Group II were stopped from taking
LNG pills due to fall in HDL level. 53 from Group II requested
incorporation in Group I and 49 were stopped completely
} }
%
Rubio-Lotvin et al, Adv Cont Deliv Syst vol 8;75-88
28. Follow up of HDL level in subjects from Group II after stopping LNG
pills
Results:
HDL at cycles Group II (monophasic) Group II (triphasic)
HDLc at 40 cycles (while on LNG-EE pills) 20.3 (±1.0) 22.5 (±1.6)
HDLc after 48 cycles (after discontinuation) 30.2 (±1.7) 29.2 (±1.5)
HDLc after 48 cycles (subjects who requested
incorporation to Group I) 36.5 (±1.2) 34.4 (±1.4)
20.3
22.5
29.2
30.2
36.5
34.4
0
5
10
15
20
25
30
35
40
Group II (monophasic) Group II (triphasic)
HDLc at 40 cycles (while on
LNG pills)
HDLc after 48 cycles (after
discontinuing)
HDLc after 48 cycles (subjects
who requested incorporation to
Group I)
Rubio-Lotvin et al, Adv Cont Deliv Syst vol 8;75-88
29. Conclusion
• 100% contraceptive efficacy with all 3 pills
• No impact on blood pressure with all 3 pills
• Minimal weight change in users of DSG-EE after 5 years of continuous use
• Increase in HDL-c component in DSG+EE is consistent with
consumption
• Anabolic effects of LNG and NET observed
Minimal side-effects, 100% contraceptive efficacy and a favorable lipid profile
make the DSG +EE combination the pill of preference
30. Systematic Review
Evaluation of various low-dose progestogen-containing
COCs and to assess their acceptability based on:
1. Effectiveness
2. Discontinuation rates and reasons for discontinuation
3. Cycle control
4. Side-effects
Lawrie TA, Helmerhorst FM,Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM. Types of progestogens in combined oral
contraception: effectiveness and side-effects. Cochrane Database of Systematic Reviews 2011, Issue 5.
31. Material and Methods
N=
Data collection
and analysis
Selection criteria
Objectives
Background
• Major determinants of effectiveness of OCPs are compliance & continuation
which may be influenced by cycle control and common side effects
• The rationale of this review is to provide a systematic comparison of COCs
containing the progestogens currently in use worldwide
• To compare currently available low-dose COCs containing ethinyl
estradiol and different progestogens in terms of contraceptive
effectiveness, cycle control, side effects and continuation rates
• Randomized trials reporting clinical outcomes were considered for inclusion.
• Excluded studies comparing monophasic with multiphasic pills, crossover trials,
trials in which the difference in total content of ethinyl estradiol between
preparations exceeded 105 μg per cycle and those comparing continuous dosing
regimens.
• Two reviewers independently assessed methodological quality, applied
inclusion criteria and extracted data
• 30 trials with a total of 13,923 participants were included
Lawrie TA, Helmerhorst FM,Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM. Types of progestogens in combined oral contraception:
effectiveness and side-effects. Cochrane Database of Systematic Reviews 2011, Issue 5.
32. Key Results: Desogestrel Vs Levonorgestrel
• Pregnancy rates were similar in both groups.
• Discontinuation due to side-effects including cycle disturbances was more
likely to occur in the LNG group (RR 0.40, 95% CI 0.19, 0.82)
Lawrie TA, Helmerhorst FM,Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM. Types of progestogens in combined oral contraception:
effectiveness and side-effects. Cochrane Database of Systematic Reviews 2011, Issue 5.
33. Key Results: Drospirenone Vs. Desogestrel
• Pregnancy and discontinuation rates were similar in both groups.
• Overall, a similar number of women in both groups reported side effects,
except for breast tenderness which was more common in the DRSP group (5
trials, 4258 women, RR 1.39, 95% CI 1.04, 1.86).
• There was a trend towards more nausea, breast tenderness and vomiting in
the DRSP group (6 trials, 4701 women, RR 1.46, 95% CI 0.96, 2.21).
Lawrie TA, Helmerhorst FM,Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM. Types of progestogens in combined oral contraception:
effectiveness and side-effects. Cochrane Database of Systematic Reviews 2011, Issue 5.
34. Summary
• Pregnancy rates overall were comparable
• Women using monophasic COC’s containing 3rd gen progestogens were less
likely to discontinue than the second-generation group
• Women in the 3rd gen group experienced less inter-menstrual bleeding than
the 2nd gen group
• Compared to Desogestrel (DSG), women in the Drospirenone (DRSP) group
were more likely to complain of breast tenderness and nausea
Lawrie TA, Helmerhorst FM,Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM. Types of progestogens in combined oral contraception: effectiveness
and side-effects. Cochrane Database of Systematic Reviews 2011, Issue 5.
35. Absolute Contraindications…
(WHO Category IV)
• Migraine, with focal Neurological Symptoms
• Severe Hypertension
• Complicated valvular heart disease
• D.M. with vascular complications
• Active hepatitis, liver tumors
• Major Surgery
• Prolonged Immobilization .
36. Indications of Withdrawal :
« Severe migraine
« Visual or speech disturbances
« Sudden chest pain
« Unexplained fainting attack or acute vertigo
« Severe leg cramps
« Excessive weight gain
« Severe depression
« Prior to surgery ( Atleast 6 weeks )
37. Interaction With Drugs…
1) Barbiturates , Sulphonamides, Rifampicin
and Anticonvulsant interfere with OC’s and
failure rate increases
2) Interaction with antidiabetic drugs
3) Vit. C aggravates the effect of COC
38. Conclusion
Higher doses of
estrogen
component have
been associated
with adverse
estrogenic events,
such as nausea,
breast tenderness
and bloating
High
Progestogenic
activity and low
androgenic
activity is a
desirable
attribute of a
progestogen
Desogestrel has a
high selectivity to
progestogenic
receptors and
low selectivity for
andorgenic
receptors
Increase in
HDL-c
component in
DSG+EE,
consistent with
consumption
Minimal side-effects, 100% contraceptive efficacy and a
favorable lipid profile make the DSG +EE combination the
pill of preference
39. ADDRESS
11 Gagan Vihar, Near
Karkari Morh Flyover,
Delhi - 51
CONTACT US
9650588339
9599044257
011-22414049
WEBSITE :
www.lifecareivf.in
www.lifecarecentre.in
www.lifecareabs.in
ISO 14001:2004 (EMS)
…..Caring hearts, healing hands
ISO 9001:2008
Helpline : 9599044257
Web.www.lifecareivf.in
Helpline : 9910081484
30
Year
In
your
service